Evolent Net Income From Continuing Ops from 2010 to 2026

EVH Stock  USD 3.21  0.03  0.93%   
Evolent Health's Net Loss is decreasing with stable movements from year to year. Net Loss is predicted to flatten to about -58.2 M. For the period between 2010 and 2026, Evolent Health, Net Loss quarterly trend regression had mean deviation of  83,963,611 and range of 654.1 M. View All Fundamentals
 
Net Loss  
First Reported
2013-03-31
Previous Quarter
-19.9 M
Current Value
-20.9 M
Quarterly Volatility
88 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Evolent Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evolent Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 148.7 M, Total Revenue of 3.1 B or Gross Profit of 443.6 M, as well as many indicators such as Price To Sales Ratio of 0.55, Dividend Yield of 0.0072 or PTB Ratio of 1.22. Evolent financial statements analysis is a perfect complement when working with Evolent Health Valuation or Volatility modules.
  
Build AI portfolio with Evolent Stock
Check out the analysis of Evolent Health Correlation against competitors.
For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.
The Net Income From Continuing Ops trend for Evolent Health offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Evolent Health is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Evolent Health's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Evolent Health over the last few years. It is Evolent Health's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evolent Health's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Evolent Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(66,422,261)
Geometric Mean62,634,404
Coefficient Of Variation(211.83)
Mean Deviation83,963,611
Median(52,658,000)
Standard Deviation140,701,365
Sample Variance19796.9T
Range654.1M
R-Value(0.23)
Mean Square Error20008.8T
R-Squared0.05
Significance0.38
Slope(6,382,085)
Total Sum of Squares316750T

Evolent Net Income From Continuing Ops History

2026-58.2 M
2025-55.5 M
2024-61.6 M
2023-113 M
2022-18.7 M
2021-30.3 M
2020-334.2 M

About Evolent Health Financial Statements

Investors use fundamental indicators, such as Evolent Health's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Evolent Health's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-55.5 M-58.2 M

Currently Active Assets on Macroaxis

When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:
Check out the analysis of Evolent Health Correlation against competitors.
For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is there potential for Health Care Technology market expansion? Will Evolent introduce new products? Factors like these will boost the valuation of Evolent Health. Projected growth potential of Evolent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.57)
Revenue Per Share
17.85
Quarterly Revenue Growth
(0.23)
Return On Assets
0.0012
Return On Equity
(0.12)
Understanding Evolent Health requires distinguishing between market price and book value, where the latter reflects Evolent's accounting equity. The concept of intrinsic value—what Evolent Health's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Evolent Health's price substantially above or below its fundamental value.
It's important to distinguish between Evolent Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evolent Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Evolent Health's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.